5th World Congress on Cancer Therapy
Advanced Individual Medicine, USA
Title: Next generation sequencing methodologies in identifying biomarkers and treatment options across cancers
Biography: Sherri Z. Millis
In the last few years with the advent of next generation sequencing, the commercial genetic and genomic testing off erings has grown signifi cantly. Multiple technologies have been employed to interrogate both familial variants and biomarker aberrations in cancer, including whole genome, whole exome, and hot spot sequencing. Th e various testing technologies are not equivalent. Th e spectrum is vast, from the number of genes interrogated, the exons (and introns) covered, the depth of sequencing, the types of genomic alterations detected, to the analytic and clinical validity. Even the accreditation, costs and reimbursement diff er. All these variables come in to play when trying to understand the limitations and strengths of each assay. Additionally, knowing when genetic and/or genomic testing is appropriate for ones patient must be included in the decision, when choosing which test to order. Interpretation of the report provided with the test results adds an additional level of complexity. Th ese reports oft en include complicated recommendations for treatment options. How these novel treatment options are generated diff ers, and determining which treatment options are relevant to consider can be overwhelming. identifi ed when utilizing genomic testing in oncology. Th e primary technologies, their similarities and diff erences, and the algorithms that inform many of the recommended treatment options will be described, along with issues in the reimbursement landscape.